Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Carcinoma, Hepatocellular 29Neoplasms 18Neoplasm Metastasis 14Melanoma 14Stomach Neoplasms 13Esophageal Neoplasms 13Colorectal Neoplasms 12Nasopharyngeal Carcinoma 11Esophageal Squamous Cell Carcinoma 10Triple Negative Breast Neoplasms 9Head and Neck Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Recurrence 8Breast Neoplasms 8Rectal Neoplasms 7Pancreatic Neoplasms 7Lung Neoplasms 7Carcinoma, Renal Cell 7Biliary Tract Neoplasms 7Small Cell Lung Carcinoma 6Colonic Neoplasms 5Cholangiocarcinoma 5Sarcoma 4Ovarian Neoplasms 4Locally Advanced Rectal Cancer 4Liver Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3

Interventions

pembrolizumab 5Oxaliplatin 3Nivolumab 3sintilimab 2Leucovorin 2Immune Checkpoint Inhibitors 2Fluorouracil 2Capecitabine 2Bevacizumab 2vicriviroc 1trifluridine tipiracil drug combination 1spartalizumab 1relatlimab 1regorafenib 1epacadostat 1dabrafenib 1copanlisib 1binimetinib 1atezolizumab 1Tiragolumab 1Irinotecan 1Fulvestrant 1E7046 1Cetuximab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Spinocerebellar Degenerations × Immune Checkpoint Inhibitors × Clear all
NCT07551479 2026-04-24

TORCH-STAR

Fudan University

Phase 3 Not yet recruiting
612 enrolled

Spinocerebellar Degenerations

NCT06835179 2025-02-19

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
28 enrolled
Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡